Dual antiplatelet therapy for secondary prevention of coronary artery disease
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
[PDF][PDF] Dual antiplatelet therapy for secondary prevention of coronary artery disease.
S Degrauwe, T Pilgrim, A Aminian, S Noble, P Meier… - Open heart, 2017 - serval.unil.ch
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
Dual antiplatelet therapy for secondary prevention of coronary artery disease.
S Degrauwe, T Pilgrim, A Aminian, S Noble, P Meier… - Open Heart, 2017 - europepmc.org
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y 12 receptor inhibitor has
been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) …
been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) …
[PDF][PDF] Dual antiplatelet therapy for secondary prevention of coronary artery disease
S Degrauwe, T Pilgrim, A Aminian, S Noble, P Meier… - receptor - core.ac.uk
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
[HTML][HTML] Dual antiplatelet therapy for secondary prevention of coronary artery disease
S Degrauwe, T Pilgrim, A Aminian, S Noble, P Meier… - Open Heart, 2017 - ncbi.nlm.nih.gov
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y 12 receptor inhibitor has
been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) …
been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) …
Dual antiplatelet therapy for secondary prevention of coronary artery disease
S Degrauwe, T Pilgrim, A Aminian, S Noble… - Open …, 2017 - pubmed.ncbi.nlm.nih.gov
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y 12 receptor inhibitor has
been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) …
been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) …
Dual antiplatelet therapy for secondary prevention of coronary artery disease.
S Degrauwe, T Pilgrim, A Aminian, S Noble, P Meier… - Open heart, 2017 - sonar.ch
English Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor
has been consistently shown to reduce recurrent major adverse cardiovascular events …
has been consistently shown to reduce recurrent major adverse cardiovascular events …
Dual antiplatelet therapy for secondary prevention of coronary artery disease.
S Degrauwe, T Pilgrim, A Aminian, S Noble, P Meier… - Open heart, 2017 - folia.unifr.ch
English Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor
has been consistently shown to reduce recurrent major adverse cardiovascular events …
has been consistently shown to reduce recurrent major adverse cardiovascular events …
[PDF][PDF] Dual antiplatelet therapy for secondary prevention of coronary artery disease
S Degrauwe, T Pilgrim, A Aminian, S Noble, P Meier… - receptor - serval.unil.ch
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …